Capital Fund Management S.A. Sells 51,122 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• Capital Fund Management S.A. has reduced its stake in Catalyst Pharmaceuticals, Inc. by 41.4%, selling 51,122 shares and now holding 72,334 shares worth approximately $1.75 million.
• Several institutional investors have increased their stakes in Catalyst Pharmaceuticals, including Bank of America, which raised its investment by 139.5% to approximately $32.7 million.
• Analysts have mixed ratings on Catalyst Pharmaceuticals, with Zacks Research and Wall Street Zen downgrading the stock to a "hold" from "strong-buy," while Cantor Fitzgerald upgraded it to a "strong-buy."

Capital Fund Management S.A. cut its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 41.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 72,334 shares of the biopharmaceutical company's stock after selling 51,122 shares during the period. Capital Fund Management S.A. owned 0.06% of Catalyst Pharmaceuticals worth $1,754,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. bought a new position in Catalyst Pharmaceuticals in the 1st quarter worth $484,000. Principal Financial Group Inc. raised its holdings in Catalyst Pharmaceuticals by 2.8% in the 1st quarter. Principal Financial Group Inc. now owns 617,506 shares of the biopharmaceutical company's stock worth $14,975,000 after purchasing an additional 17,018 shares during the period. Spire Wealth Management raised its stake in shares of Catalyst Pharmaceuticals by 27.7% in the first quarter. Spire Wealth Management now owns 18,429 shares of the biopharmaceutical company's stock worth $447,000 after buying an additional 4,000 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in shares of Catalyst Pharmaceuticals by 65.0% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 35,334 shares of the biopharmaceutical company's stock worth $857,000 after buying an additional 13,915 shares during the period. Finally, Assenagon Asset Management S.A. bought a new position in shares of Catalyst Pharmaceuticals in the first quarter worth about $2,343,000. 79.22% of the stock is currently owned by institutional investors.

Insider Activity at Catalyst Pharmaceuticals

In other news, CEO Richard J. Daly sold 22,970 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, August 26th. The stock was sold at an average price of $20.62, for a total value of $473,641.40. Following the sale, the chief executive officer directly owned 226,794 shares of the company's stock, valued at approximately $4,676,492.28. The trade was a 9.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Preethi Sundaram sold 1,600 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total value of $42,272.00. Following the completion of the sale, the insider directly owned 41,081 shares in the company, valued at approximately $1,085,360.02. The trade was a 3.75% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 167,894 shares of company stock valued at $3,434,690. 10.40% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on CPRX shares. Zacks Research cut shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Catalyst Pharmaceuticals currently has an average rating of "Buy" and an average price target of $33.20.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock traded up $0.21 on Friday, hitting $20.59. 814,373 shares of the company traded hands, compared to its average volume of 1,497,881. The stock has a market capitalization of $2.52 billion, a P/E ratio of 12.48, a price-to-earnings-growth ratio of 0.84 and a beta of 0.85. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.00 and a 52 week high of $26.58. The business has a 50-day simple moving average of $21.02 and a 200 day simple moving average of $22.51.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.